What is NKTX (NKTX) stock price today?

NKTX (NKTX) is currently trading at $2.92, up 4.66% today.

What is NKTX P/E ratio?

NKTX's P/E ratio is -1.78. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is NKTX return on equity (ROE)?

NKTX's return on equity (ROE) is -39.64%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is NKTX's market cap?

NKTX has a market capitalization of $208.91M.

NASDAQ · Biotechnology

NKTX (NKTX) Stock

$2.92 +4.66% NASDAQ: NKTX Healthcare

Valuation

Metric	Value
Price	$2.92
Market Cap	$208.91M
P/E Ratio	-1.78
P/B Ratio	0.84
P/S Ratio	0.00
EPS (TTM)	$-1.41
52-Week High	$3.72
52-Week Low	$1.70
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-39.64%
ROA	-34.75%
ROCE	-42.11%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.30
Current Ratio	12.86

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-86.0M	$-119.0M	$-132.0M	$-128.0M	$-121.0M
Net Profit	$-86.0M	$-114.0M	$-118.0M	$-109.0M	$-104.0M
EPS	$-2.62	$-2.61	$-2.40	$-1.60	$-1.41
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$274.0M	$473.0M	$379.0M	$501.0M	$404.0M
Total Liabilities	$23.0M	$101.0M	$106.0M	$93.0M	$92.0M
Cash	$61.0M	$37.0M	$31.0M	$28.0M	$40.0M
Borrowings	$12.0M	$83.0M	$88.0M	$80.0M	$76.0M

Latest News

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference GlobeNewswire · Jun 26, 2026 TD Cowen Initiates Nkarta at Buy MT Newswires · Jun 23, 2026 Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation Simply Wall St. · May 14, 2026 Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights GlobeNewswire · May 12, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-68.0M	$-57.0M	$-86.0M	$-100.0M	$-89.0M
Investing Cash Flow	$28.0M	$-232.0M	$51.0M	$-134.0M	$99.0M
Financing Cash Flow	$0	$2.0M	$0	$1.0M	$0
Net Cash Flow	$-34.0M	$-23.0M	$-6.0M	$-3.0M	$12.0M
Free Cash Flow	$-73.0M	$-104.0M	$-114.0M	$-104.0M	$-90.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.19
EV / EBITDA	-2.30
FCF Yield	-47.04%
Quick Ratio	7.98
Interest Coverage	0.00
Return 1Y	40.21%
Return 3Y	33.17%
Return 5Y	-91.16%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALEC	$2.46	-1.99%	-2.28	$273.12M	0.00%
APLTApplied Therapeutics, Inc.	$0.10	+0.00%	-0.24	$14.86M	0.00%
CYBNCybin Inc.	$8.28	+1.22%	-1.67	$413.02M	0.00%
ELTX	$2.41	-3.60%	-1.47	$45.95M	0.00%
FATE	$2.48	+2.48%	-2.30	$289.07M	0.00%

About NKTX

NKTX is led by CEO Paul J. Hastings, publicly traded since 2020.

NKTX stock trades at $2.92 with a market capitalization of $208.91M. The stock is valued at a price-to-earnings (P/E) ratio of -1.78, price-to-book of 0.84, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.70 and $3.72, and currently trades 21.5% below its 52-week high.

On profitability, NKTX generates a return on equity (ROE) of -39.64%, return on capital employed of -42.11%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides